Page 178 - SAMRC AnnualReport 2025-26

KEY COMPONENTS OF SAMVAC

The SAMVAC consortium has grown considerably mRNA vaccines for TB. Following the evaluation of
over the past 4 years with the addition of new multiple candidates, two mRNA vaccine constructs
consortium members and substantial progress were selected for further preclinical development,
has been made in the R&D programmes under the with substantial preclinical data supporting their
following thematic areas. movement to first in human studies. Efforts have
now shifted towards scaling up production under
The TB TITAN (Towards a First-In-Human Trial of GMP conditions and confirmatory preclinical
the TCR-Informed ANtigen) vaccine development testing. A draft Phase I clinical trial plan is under
programme is led by the SATVI team at UCT in development to guide planning and fund raising
collaboration with the AGTRU Wits team and for a first-in-human evaluation of both vaccine
Afrigen. TB TITAN aims to develop candidate candidates.

TB TITAN stakeholders annual face-to-face meeting held at the Vineyard Hotel, Cape Town,
on 7 August 2025.

176 SA M R C A N N U A L R EP O R T 2 0 2 5 / 2 0 2 6